Benzinga's Top #PreMarket Gainers

Exelixis EXEL shares gained 12.78% to $3.75 in pre-market trading after the company reported that coBRIM has met primary endpoint in phase 3 trial. Progenics Pharmaceuticals PGNX shares surged 11.08% to $4.71 in pre-market trading. Salix Pharmaceuticals SLXP and Progenics reported that the FDA Office of Drug Evaluation III has approved Salix request for the FDA approval of RELISTOR sNDA. URS URS shares jumped 7.92% to $56.14 in pre-market trading after Aecom Technology ACM announced its plans to buying URS for $4 billion in cash and stock. Mylan MYL shares gained 3.59% to $52.00 in pre-market trading after the company announced its plans to acquire Abbott's ABT non-U.S. developed markets specialty and branded generics business in a $5.3 billion all-stock transaction.